Adult patients with unresectable, locally advanced or metastatic, hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The gene discussed is NR4A1; the disease is breast carcinoma.